Urinary Extracellular Vesicles as Markers of Tubular Adaptation

Abstract

Urinary extracellular vesicles (uEVs) have emerged as promising non-invasive biomarkers reflecting tubular adaptation in various renal pathologies. These nanoscale vesicles, released by renal tubular cells, encapsulate proteins, lipids, and nucleic acids indicative of the physiological and pathological state of the tubular microenvironment. Recent advances highlight their utility in monitoring renal injury, adaptation, and repair, while providing unique mechanistic insights and offering potential for clinical translation. This review synthesizes current evidence on the role of uEVs as markers of tubular adaptation, focusing on their pathophysiological relevance, diagnostic potential, and integration into clinical practice, with emphasis on emerging research and guideline-based recommendations.

Introduction

Renal tubular adaptation is a critical process in response to physiological stressors or injury, mediating recovery and maintaining renal homeostasis. Traditional methods for assessing tubular function and injury, such as serum creatinine or urinary protein excretion, lack specificity and sensitivity, particularly for early or subclinical changes. In recent years, urinary extracellular vesicles (uEVs) including exosomes, microvesicles, and apoptotic bodies have been recognized as reflective of dynamic tubular cell processes. By encapsulating specific molecular signatures, uEVs hold promise as novel, non-invasive biomarkers for detecting tubular adaptation, providing both diagnostic and mechanistic information. This review examines the role of uEVs in identifying and characterizing tubular adaptation, with a focus on their clinical and translational implications.

Epidemiology / Disease Burden

Tubular adaptation is a fundamental process implicated in a wide range of renal diseases, including acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, and hypertensive nephrosclerosis. Globally, CKD affects approximately 13% of the population, with tubular dysfunction contributing significantly to disease progression and adverse outcomes. The burden of renal disease is further compounded by the high prevalence of risk factors such as diabetes and hypertension. Conventional markers often fail to detect early tubular alterations, underscoring the need for advanced, non-invasive biomarkers like uEVs, which could improve risk stratification and management in these high-burden patient populations.

Pathophysiology

Urinary extracellular vesicles originate from all segments of the nephron, especially tubular epithelial cells. Their biogenesis involves endosomal sorting or direct shedding from the plasma membrane, processes that are dynamically regulated by cellular stress, injury, or adaptation. In response to ischemia, toxins, or hyperglycemia, tubular cells modulate the content and release of uEVs, incorporating stress markers (e.g., neutrophil gelatinase-associated lipocalin, KIM-1), transporters (e.g., aquaporins, sodium-hydrogen exchangers), and signaling molecules (e.g., microRNAs). These molecular cargos provide real-time snapshots of tubular cellular adaptation, injury, and repair mechanisms, enabling the distinction between adaptive and maladaptive responses that drive progression to fibrosis or recovery.

Risk Factors

Several factors influence the release and composition of uEVs, reflecting the risk and severity of tubular adaptation. Notable risk factors include diabetes mellitus, hypertension, nephrotoxin exposure (e.g., aminoglycosides, cisplatin), sepsis, and volume depletion. Genetic predisposition and underlying chronic kidney disease further modulate tubular susceptibility and adaptive capacity. These risk factors not only increase the burden of tubular injury but also alter the molecular signature of uEVs, presenting an opportunity for personalized risk assessment and early intervention.

Clinical Features

While tubular adaptation itself is not directly symptomatic, its failure or maladaptation contributes to clinical manifestations such as oliguria, electrolyte imbalances, and progressive loss of renal function. Traditional clinical features of underlying renal diseases may be nonspecific, necessitating adjunctive biomarkers. Molecular analysis of uEVs can reveal subclinical tubular stress or adaptation before overt clinical or laboratory abnormalities emerge, providing a window for earlier diagnosis and intervention. For example, increased urinary levels of exosomal aquaporin-2 may indicate adaptive responses in water reabsorption, while elevated KIM-1 or NGAL in uEVs can signal early tubular injury.

Diagnosis

The diagnostic application of uEVs involves isolation from urine samples, followed by characterization using proteomic, lipidomic, and transcriptomic techniques such as mass spectrometry, Western blotting, and next-generation sequencing. Several studies have demonstrated that specific uEV markers correlate with histopathological and functional indices of tubular adaptation, outperforming conventional biomarkers. For example, in AKI, uEV-derived microRNAs and protein markers can differentiate adaptive repair from ongoing injury, while in CKD, changes in uEV cargo reflect disease severity and response to therapy. Standardization of analytical workflows and validation in larger cohorts remain critical for clinical translation.

Treatment & Management

Although uEVs themselves are not therapeutic targets, their use as biomarkers can guide individualized management of renal diseases by facilitating early detection of tubular adaptation or injury and monitoring therapeutic response. Adjustments in nephrotoxin exposure, glycemic control, and volume management can be tailored based on uEV profile dynamics. Moreover, serial monitoring of uEVs may help optimize the timing of interventions, assess efficacy of renoprotective agents, and minimize progression to irreversible damage ultimately improving patient outcomes.

Recent Advances / Emerging Therapies

Recent research has focused on refining uEV isolation techniques and expanding the catalog of clinically relevant uEV markers. Studies have identified novel microRNAs and protein signatures associated with adaptive versus maladaptive tubular responses, with potential applications in precision medicine. Emerging therapies targeting vesicle-mediated signaling pathways are under investigation, raising the possibility of modulating tubular adaptation in situ. In addition, point-of-care assays for rapid uEV profiling are being developed, bringing the field closer to routine clinical implementation. Ongoing clinical trials and multi-center studies will further validate these advances and define their role in clinical practice.

Guideline Recommendations

Current clinical guidelines for kidney disease emphasize the importance of early detection and risk stratification but do not yet formally incorporate uEVs into routine practice. However, expert consensus statements from nephrology societies acknowledge the potential of uEVs as adjunctive biomarkers for tubular function and adaptation. Recommendations highlight the need for standardization of uEV analysis, multicenter validation studies, and integration with existing clinical algorithms. As evidence accrues, future updates to guidelines are expected to address the clinical utility of uEVs in diagnosis, prognosis, and therapeutic monitoring

Conclusion

Urinary extracellular vesicles represent a transformative frontier in nephrology, offering sensitive, specific, and mechanistically informative biomarkers of tubular adaptation. Their integration into clinical practice promises to enhance early detection, guide personalized management, and improve outcomes across a spectrum of renal diseases. Continued research, technological refinement, and guideline harmonization will be essential to realize their full potential in advancing kidney health.